Niacin Ameliorates Lipid Disturbances due to Glucocorticoid Administration in Rats


1 Division of Physiology, Department of Basic Sciences, School of Veterinary Medicine, Shiraz University, Shiraz, Iran

2 Division of Pharmacology and Toxicology, Department of Basic Sciences, School of Veterinary Medicine, Shiraz University, Shiraz, Iran


This study was conducted to evaluate the effects of niacin on glucocorticoid-induced dyslipidemia and fatty liver in rats.
Materials and Methods
Twenty four adult male rats were divided randomly into four equal groups: 1- normal saline (control), 2- dexamathasone 0.125 mg/kg/day, i.m., 3- dexamathasone + niacin 200 mg/kg/day, oral gavages, 4- niacin. After 2 weeks, serum total cholesterol, triglycerides, HDL-c, LDL-c and VLDL-c concentrations were assayed and liver sections examined for fatty liver changes. Data were analyzed by ANOVA method and         P< 0.05 was considered significant.
Dexamethasone increased all lipid parameters as compared to control (P< 0.05). Lipid parameters in group 3, were lower than group 2 (P< 0.05) except for HDL-c which remained statistically the same. Moderate fatty liver changes were observed in one third of rats in dexamethasone group. Rats in groups 1, 3 and 4 had no sign of fatty changes.
Niacin positively affects glucocorticoid-induced dyslipidemia and fatty liver changes in rats.


1. Schimmer BP, Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Goodman and Gilman's the Pharmacological Basis of Therapeutics. 10th ed. United states of America: McGraw-Hill; 2001. p.1649-1677.
2. Plumb DC. Plumb's Veterinary Drug Handbook. 6th ed. Iowa: Blackwell Publishing; 2008.
3. Jefferys DB, Lessof MH, Mattock MB. Corticosteroid treatment, serum lipids and coronary artery disease. Postgrad Med J 1980; 56:491-493.
4. Mitamura T. Glucocorticoid-induced elevation of serum high-density lipoprotein-cholesterol and its reversal by adrenocorticotropin in the rat. Biochim Biophys Acta  1987; 917:121-130.
5. Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol  2000; 16:505-511.
6. Arnaldi G, Scandali VM, Trementino L, Cardinaletti M, Appolloni G, Boscaro M. Pathophysiology of dyslipidemia in Cushing's syndrome. Neuroendocrinology 2010; 92:86-90.
7. Letteron P, Brahimi-Bourouina N, Robin MA, Moreau A, Feldmann G, Pessayre D. Glucocorticoids inhibit mitochondrial matrix acyl-CoA dehydrogenases and fatty acid beta-oxidation. Am J Physiol  1997; 272:1141-1150.
8. Westphal S, Borucki K, Taneva E, Makarova R, Luley C. Extended-release niacin raises adiponectin and leptin. Atherosclerosis 2007; 193:361-365.
9. Bagdade JD,Yee E, Albers J, Pykalisto OJ. Glucocorticoids and triglyceride transport: effects on triglyceride secretion rates, lipoprotein lipase, and plasma lipoproteins in the rat. Metabolism  1976; 25:533-542.
10. Barboriak JJ, Meade RC. Nicotinic acid and alcohol-induced lipemia. Atherosclerosis 1971; 13:199-203.
11. Vegiopoulos A, Herzig S. Glucocorticoids, metabolism and metabolic diseases. Mol Cell Endocrinol 2007; 275:43-61.
12. Jin FY, Kamanna VS, Kashyap ML. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. Arterioscler Thomb Vasc Biol 1997; 17:2020 –2028.
13. Ganji SH, Tavintharan S, Zhu D, Xing Y, Kamanna VS, Kashyap ML. Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res  2004; 45:1835–1845.
14. Shepherd J, Betteridge J, Van Gaal L. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Curr Med Res Opin 2005; 21:665-682.
15. Cole TG, Wilcox HG, Heimberg M. Effects of adrenalectomy and dexamethasone on hepatic lipid metabolism. J Lipid Res 1982; 23:81-91.